Supplementary Figure 4. Mechanism of inhibition by compound 12. (a)
In vivo accumulation of reduced DsbB when incubating cells with compound 12. Cells were grown aerobically with different concentrations of drug and precipitated proteins were treated with Maleimide-PEG2k (ME2k, 2kDa). Samples were run on reducing SDS-PAGE and immunoblotted against anti-DsbB. Dithiothreitol (DTT) was used for reducing disulfide bonds prior to alkylation. "oxidized" refers to the position of the oxidized protein which is the same as that of the protein with all four cysteines (Cys) mutated. "Reduced" refers to bands where the positions of the protein with the four or indicated number of reduced cysteines are detected due to alkylation which adds to the molecular weight. Gel shown is a representative immunoblot of two independent experiments. (b) Visible absorbance spectra of DsbB and DsbB-DsbA C33A dimer. The pink color of the DsbB-ubiquinone charge-transfer complex diminishes when compound 12 is added, indicating disruption of the interaction between Cys44 of DsbB and the cofactor ubiquinone. DsbB or DsbB-DsbA C33A complex (each at 100 µM) were mixed with compound 12 (or with DMSO) at 1:2 molar ratio in 50 mM Tris buffer pH 8.0 containing 300 mM NaCl and 0.05% DDM. Samples were incubated on ice for about 4 minutes before the spectra were recorded using 1 cm quarts cuvettes. Supplementary analysis of compound 12 purity. Purity of compound 12: 95%, assessed by HPLC-MS (Vendor and ICCB) and NMR (Vendor).
Supplementary analysis of proteins purity.
The purity of the enzymes used in this study is over 95% for the three of them and was assessed by SDS-PAGE (12% acrylamide gels and Coomassie Briliant Blue staining). A representative image is shown below. The sequences of all of them are also indicated. 
